Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118702963> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W3118702963 endingPage "748" @default.
- W3118702963 startingPage "736" @default.
- W3118702963 abstract "Despite continued and considerable progress following the introduction of proteasome inhibitors and immunomodulatory agents, multiple myeloma (MM) remains an incurable disease, and new therapeutic strategies are urgently needed. Monoclonal antibodies represent a well-established targeted approach to the treatment of MM, with selective killing properties and limited off-target toxicity. Since their approval, the anti-CD38 agent daratumumab, the anti-SLAMF7 agent elotuzumab, and most recently the anti-CD38 agent isatuximab have led to pivotal improvements in the treatment of double-refractory MM; currently, they are on their way to becoming integral parts in the up-front care of patients who have newly diagnosed MM, with daratumumab already approved in this setting. Several other antibody-based strategies are undergoing clinical assessment in MM. Although the investigation of checkpoint inhibitors in MM has been halted, bispecific T-cell engagers and especially antibody-drug conjugates demonstrate encouraging efficacy and manageable toxicity in triple class-refractory MM. The accelerated approval of belantamab mafodotin represents an important milestone in antibody development; its ability to target B-cell maturation antigen (BCMA) in advanced disease is now established. Here, we present an overview of the currently available monoclonal antibody treatments in MM and discuss the clinical value, significant potential, and possible limitations of these immunotherapeutic approaches to driving deeper responses and achieving longer overall survival among patients with a challenging disease." @default.
- W3118702963 created "2021-01-18" @default.
- W3118702963 creator A5037996029 @default.
- W3118702963 creator A5043526996 @default.
- W3118702963 creator A5068511166 @default.
- W3118702963 creator A5085953389 @default.
- W3118702963 date "2020-11-01" @default.
- W3118702963 modified "2023-09-23" @default.
- W3118702963 title "Current antibody-based therapies for the treatment of multiple myeloma." @default.
- W3118702963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33406065" @default.
- W3118702963 hasPublicationYear "2020" @default.
- W3118702963 type Work @default.
- W3118702963 sameAs 3118702963 @default.
- W3118702963 citedByCount "0" @default.
- W3118702963 crossrefType "journal-article" @default.
- W3118702963 hasAuthorship W3118702963A5037996029 @default.
- W3118702963 hasAuthorship W3118702963A5043526996 @default.
- W3118702963 hasAuthorship W3118702963A5068511166 @default.
- W3118702963 hasAuthorship W3118702963A5085953389 @default.
- W3118702963 hasConcept C121608353 @default.
- W3118702963 hasConcept C126322002 @default.
- W3118702963 hasConcept C143998085 @default.
- W3118702963 hasConcept C159654299 @default.
- W3118702963 hasConcept C203014093 @default.
- W3118702963 hasConcept C2776364478 @default.
- W3118702963 hasConcept C2777701055 @default.
- W3118702963 hasConcept C2778020697 @default.
- W3118702963 hasConcept C2778957590 @default.
- W3118702963 hasConcept C2780057760 @default.
- W3118702963 hasConcept C2781119759 @default.
- W3118702963 hasConcept C3020495827 @default.
- W3118702963 hasConcept C542903549 @default.
- W3118702963 hasConcept C71924100 @default.
- W3118702963 hasConceptScore W3118702963C121608353 @default.
- W3118702963 hasConceptScore W3118702963C126322002 @default.
- W3118702963 hasConceptScore W3118702963C143998085 @default.
- W3118702963 hasConceptScore W3118702963C159654299 @default.
- W3118702963 hasConceptScore W3118702963C203014093 @default.
- W3118702963 hasConceptScore W3118702963C2776364478 @default.
- W3118702963 hasConceptScore W3118702963C2777701055 @default.
- W3118702963 hasConceptScore W3118702963C2778020697 @default.
- W3118702963 hasConceptScore W3118702963C2778957590 @default.
- W3118702963 hasConceptScore W3118702963C2780057760 @default.
- W3118702963 hasConceptScore W3118702963C2781119759 @default.
- W3118702963 hasConceptScore W3118702963C3020495827 @default.
- W3118702963 hasConceptScore W3118702963C542903549 @default.
- W3118702963 hasConceptScore W3118702963C71924100 @default.
- W3118702963 hasIssue "11" @default.
- W3118702963 hasLocation W31187029631 @default.
- W3118702963 hasOpenAccess W3118702963 @default.
- W3118702963 hasPrimaryLocation W31187029631 @default.
- W3118702963 hasRelatedWork W2140698733 @default.
- W3118702963 hasRelatedWork W2331857836 @default.
- W3118702963 hasRelatedWork W2532841680 @default.
- W3118702963 hasRelatedWork W2556720035 @default.
- W3118702963 hasRelatedWork W2751350739 @default.
- W3118702963 hasRelatedWork W2802999916 @default.
- W3118702963 hasRelatedWork W2914133986 @default.
- W3118702963 hasRelatedWork W2931051678 @default.
- W3118702963 hasRelatedWork W2989981356 @default.
- W3118702963 hasRelatedWork W2994171813 @default.
- W3118702963 hasRelatedWork W3032942728 @default.
- W3118702963 hasRelatedWork W3041796883 @default.
- W3118702963 hasRelatedWork W3046528414 @default.
- W3118702963 hasRelatedWork W3089287956 @default.
- W3118702963 hasRelatedWork W3092155144 @default.
- W3118702963 hasRelatedWork W3160171993 @default.
- W3118702963 hasRelatedWork W3161042173 @default.
- W3118702963 hasRelatedWork W3164945147 @default.
- W3118702963 hasRelatedWork W3195221202 @default.
- W3118702963 hasRelatedWork W2187882035 @default.
- W3118702963 hasVolume "18" @default.
- W3118702963 isParatext "false" @default.
- W3118702963 isRetracted "false" @default.
- W3118702963 magId "3118702963" @default.
- W3118702963 workType "article" @default.